Teva- Pharmaceutical Industries Ltd
Research Teva- Pharmaceutical Industries Ltd (TEVA) on Bullrun: valuation model: 53.1% overvalued, market cap USD 47.88B, P/E 69.1. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerTEVA
- ExchangeNYSE
- CountryIsrael
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Valuation signal53.1% overvalued
- Market capUSD 47.88B
- P/E69.1
- Financial periodQ2 2026
- RevenueUSD 4.14B
- Net income-USD 576.00M
- Free cash flowUSD 307.00M
- Gross margin52.0%
Valuation Snapshot
Bullrun's latest valuation model marks Teva- Pharmaceutical Industries Ltd as 53.1% overvalued; latest market cap is USD 47.88B; P/E is 69.1.
Peer valuation comparison
Latest P/E is 69.11x versus a Healthcare sector median of 24.6x (180.9% above).
Latest P/E is 69.11x versus a Israel median of 24.85x (178.1% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 17.26B | USD 1.41B | USD 1.15B | 51.8% | 1.21 | USD 3.56B | USD 1.82B | USD 7.91B |
| FY2024 | USD 16.54B | -USD 1.64B | USD 749.00M | 48.7% | -1.45 | USD 3.30B | USD 1.78B | USD 5.37B |
| FY2023 | USD 15.85B | -USD 559.00M | USD 842.00M | 48.2% | -0.5 | USD 3.23B | USD 1.67B | USD 7.51B |
| FY2022 | USD 14.93B | -USD 2.45B | USD 1.04B | 46.7% | -2.2 | USD 2.80B | USD 2.11B | USD 7.80B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 47.88B | 69.1 | n/a | n/a |
| 2025 | 2025-12-31 | USD 35.89B | 25.6 | n/a | n/a |
| 2024 | 2024-12-31 | USD 24.99B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 11.70B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 10.13B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 8.84B | 21.1 | n/a | n/a |
About Teva- Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms;
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Teva- Pharmaceutical Industries Ltd overvalued or undervalued?
Bullrun's valuation model currently marks Teva- Pharmaceutical Industries Ltd as 53.1% overvalued.
What is Teva- Pharmaceutical Industries Ltd's market cap?
Teva- Pharmaceutical Industries Ltd's market capitalization is USD 47.88B.
What is Teva- Pharmaceutical Industries Ltd's P/E ratio?
Teva- Pharmaceutical Industries Ltd's price-to-earnings (P/E) ratio is 69.1.
What does Teva- Pharmaceutical Industries Ltd do?
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.